Endothelial Function in Patients With Pulmonary Arterial Hypertension

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

July 31, 2016

Conditions
Hypertension, PulmonaryPulmonary Arterial HypertensionPathophysiologyGenetics
Interventions
DEVICE

EndoPAT measurement

EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.

BIOLOGICAL

Blood Test

It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.

Trial Locations (1)

20246

Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Actelion

INDUSTRY

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter